Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal of Starry Shares

23 Jul 2020 09:50

RNS Number : 8843T
Cathay International Holdings Ld
23 July 2020
 

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

Cathay International Holdings Limited ("Cathay" or the "Company")

Disposal of Starry Shares

Hong Kong, 23 July 2020 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, announces that further to the approvals granted by Cathay's shareholders on 15 May 2020 and by the shareholders of its subsidiary, Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), on 13 July 2020, Lansen has further disposed on-market of an aggregate of 424,000 shares in Zheijang Starry Pharmaceutical Co., Ltd (Starry) at the price of RMB 78.10 per Starry Shares on 23 July 2020. The selling price of RMB 78.10 represented 6 per cent discount to the closing price of Starry Shares on the Shanghai Stock Exchange on 22 July 2020.

The gross sale proceeds of disposal were approximately RMB33.11 million and, after deducting transaction costs and related tax, expected to be approximately RMB31.18 million (approximately US$4.46 million). Lansen is expected to recognise a net gain of approximately USD 3.96 million, of which USD 2.09 million is attributable to Cathay. The above-mentioned US$ amounts are converted based on the exchange rate of US$1=RMB6.9921, and the actual exchange rate used in conversion may be different.

As at the date of this announcement after the disposal of Starry Shares, 4,718,855 Shares are owned by the Lansen group (representing approximately 2.01% in Starry), which value will be subject to market price fluctuations.

The full text of the Lansen Announcement can be found at https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0723/2020072300458.pdf and will also be made available at the Announcements & Notices section of Lansen's homepage at http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.

- ENDS -

For further enquiries, please contact:

 

Cathay International Holdings Limited

Eric Siu (Finance Director) Tel: +852 2828 9289

Patrick Sung (Director and Controller)

 

 SPARK Advisory Partners Limited (sponsor)

Andrew Emmott / James Keeshan Tel: +44 (0) 20 3368 3555

 

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-products; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

 

The Group employs approximately 1,300 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

 

About Lansen

Lansen, whose shares are listed on the main board of the Hong Kong Stock Exchange, is a 52.83% owned subsidiary of Cathay. Lansen is engaged in the manufacture, distribution and development of specialty prescription drugs for treatment of autoimmune disorder in rheumatology and dermatology. Lansen has established an extensive distribution network, covering more than 1,500 hospitals in four municipalities, 22 provinces and cities in the PRC. For more information please visit the Lansen's website: www.lansen.com.cn/en/index.aspx.

 

About Starry

Starry, whose shares are listed on the Shanghai Stock Exchange (stock code: 603520). Starry is specialised in the research and development, manufacture, marketing and sales of bulk pharmaceuticals and intermediates. One of the core products of Starry is iohexol for X-CT non-ionic contrast agents. Starry is the largest generic drug manufacturer of iohexol's active pharmaceutical ingredients in the PRC and is experienced in the production management and quality control of bulk pharmaceuticals. For more information please visit Starry's website: www.starrypharm.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DISKKNBQFBKKAOB
Date   Source Headline
1st Dec 20205:39 pmRNSCompulsory Acquisition Notice
11th Nov 20209:46 amRNSResults of the Tender Offer
3rd Nov 202010:53 amRNSResult of SGM and Notification of change to Shares
3rd Nov 202010:08 amRNSLansen's seventh share reduction plan of Starry
2nd Nov 202010:11 amRNSDisposal of Starry Shares
29th Oct 202010:43 amRNSTotal Voting Rights
16th Oct 20206:16 pmRNSTender Offer and Notice of SGM
29th Sep 20201:14 pmRNSRequisition Notice
22nd Sep 202010:41 amRNSResults of Annual General Meeting
28th Aug 202012:10 pmRNSInterim Results
28th Aug 202011:57 amRNSNotice of AGM
27th Aug 20202:33 pmRNSLansen's Interim Results
21st Aug 202011:06 amRNSSecond Price Monitoring Extn
21st Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amRNSNotice of Interim Results 2020
3rd Aug 202011:21 amRNSBLOCK LISTING SIX MONTHLY RETURN
23rd Jul 20209:50 amRNSDisposal of Starry Shares
22nd Jul 202011:46 amRNSDisposal of Starry Shares
17th Jul 202012:12 pmRNSDisposal of Starry Shares
14th Jul 202010:09 amRNSTRANSFER OF LISTING
13th Jul 202011:17 amRNSPoll results of Lansen’s EGM
24th Jun 202010:46 amRNSDespatch of Circular by Lansen
15th Jun 202010:32 amRNSResult of General Meeting (“GM”)
5th Jun 20209:52 amRNSLansen update re Proposed Disposal
29th May 20202:18 pmRNSTotal Voting Rights
28th May 20202:49 pmRNSProposed transfer of listing and Notice of GM
21st May 20202:44 pmRNSTR-1: Notification of major holdings
20th May 20205:20 pmRNSTR-1: Notification of major holdings
18th May 20201:34 pmRNSDirector/PDMR Shareholding
24th Apr 20201:02 pmRNSPublication of Prospectus
21st Apr 20209:07 amRNSPublication and posting of Annual Report
9th Apr 202010:51 amRNSLansen's sixth share reduction plan of Starry
1st Apr 202010:39 amRNSAnnual Results for the year ended 31 December 2019
31st Mar 20202:37 pmRNSLansen reports annual results year ended 31 Dec 19
18th Mar 20207:00 amRNSNotice of Results
28th Feb 20207:00 amRNSTotal Voting Rights
11th Feb 20202:36 pmRNSTrading Update
3rd Feb 20207:00 amRNSBlock listing Six Monthly Return
30th Jan 20207:00 amRNSTreasury Shares,Share Capital,Total Voting Rights
27th Dec 20199:19 amRNSIncrease in shareholder loan
20th Dec 201911:36 amRNSUpdate re Board of Directors
12th Dec 201911:29 amRNSDisposal of Starry Shares
22nd Nov 201911:31 amRNSNew shareholder loan
31st Oct 20199:57 amRNSRetirement of an Executive Director
31st Oct 20197:12 amRNSTotal Voting Rights
30th Sep 20197:00 amRNSTotal Voting Rights
25th Sep 201910:36 amRNSDisposal of Starry Shares
18th Sep 201912:10 pmRNSDisposal of Starry Shares
11th Sep 201911:37 amRNSLansen's fifth share reduction plan of Starry
10th Sep 20193:10 pmRNSDisposal of Starry Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.